Yuan Yuan, PhD

AstraZeneca, Gaithersburg, MD, USA

Disclosure: AstraZeneca (Employee, Shareholder)

Presentation(s):

• LB5 - PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

  Thursday, September 30, 2021
  6:15 PM – 6:30 PM EDT

• LB13 - The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection

  Saturday, October 2, 2021
  1:15 PM – 3:00 PM EDT